Upgrade to SI Premium - Free Trial

Anthem (ANTM) Tops Q1 EPS by 17c, Revenues Beat, Enrollment Up 905K; Raises FY19 EPS Guidance Above Consensus

April 24, 2019 6:03 AM

Anthem (NYSE: ANTM) reported Q1 EPS of $6.03, $0.17 better than the analyst estimate of $5.86. Revenue for the quarter came in at $24.4 billion versus the consensus estimate of $24.28 billion.

"Our first quarter 2019 results represent a strong start to the year. We reported significant growth in our risk-based membership and improved the penetration of our clinical and specialty services, demonstrating that our value proposition is resonating across our markets," said Gail K. Boudreaux, President and CEO. "Looking ahead, the upcoming launch of IngenioRx is a key milestone in the realization of our vision and strategy. With IngenioRx, we finally have a strong integrated pharmacy and medical platform, one that is predicated on providing the lowest absolute cost of care, and we are well positioned for accelerated growth."


Anthem sees FY2019 EPS of $19.20, versus the consensus of $19.16. Anthem sees FY2019 revenue of $100 billion, versus the consensus of $100.5 billion.

For earnings history and earnings-related data on Anthem (ANTM) click here.


Corporate News Earnings Guidance Hot Corp. News Hot Guidance Management Comments

Next Articles